Microbot Medical Inc.

NASDAQ:MBOT

Medical - Instruments & Supplies

Healthcare
$0.98 -2.93%

-$0.06 today

Market cap
$65.73M
Beta
1.04
P/E (TTM)
-8.6
EPS (TTM)
-$0.21
52W Low $1.60High $4.67

Volume 0.87M

Average 1.60M

MBOT Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Microbot Medical Inc.NASDAQ: MBOT

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow outflow shrinks to $0

Q1 FY2026 financing cash flow was $0, compared with $27.81M a year earlier. Trailing-twelve-month financing cash flow was $58.43M. Over 3 fiscal years it compounded at +171.2% a year.

Context

  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $14.61M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$86.24M+986.7% YoY
LTMMar 2026
$58.43M+75.2% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+986.7%——
3-year CAGR+171.2%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
86.24M USD
Year-over-year change
+986.7%

Financing Cash Flow vs competitors

How MBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +75.2% is the 7th highest of 10, against a peer median of +538.0%.
  • Financing cash flow amounts to 55651.4% of revenue for MBOT, versus a peer median of 2758.4%.
MBOT Competitors
Financing Cash Flow for MBOT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DCGODocGo Inc.LTM Mar 2026$2.46T USD+7752625.5%+101.8%816908.1%
OVIDOvid Therapeutics Inc.LTM Mar 2026$164.18M USD+40238.1%+646.7%2305.2%
MBOTMicrobot Medical Inc.LTM Mar 2026$58.43M USD+75.2%+171.2%55651.4%
VANIVivani Medical, Inc.LTM Mar 2026$33.16M USD+538.4%-28.4%—
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$29.19M CAD+55.7%——
RCELAVITA Medical, Inc.LTM Mar 2026$20.67M USD+538.0%+155.1%28.6%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$15.14M USD-54.2%——
CLNNClene Inc.LTM Mar 2026$14.08M USD+1110.6%-12.6%10506.7%
ZTEKZentek Ltd.LTM Mar 2026CA$4.58M CAD+152.1%—2758.4%
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD-100.0%-46.9%—
Peer median (excluding MBOT) —+538.0%+44.6%2758.4%

Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(11.31M)(13.17M)(10.74M)(11.44M)(13.14M)
Depreciation & Amortization76K102K106K91K47K
Deferred Income Tax00000
Stock-Based Compensation1.39M1.75M1.39M1.35M1.06M
Change in Working Capital497K(228K)(11K)942K(1.01M)
Accounts Receivables00000
Inventory0000(584K)
Accounts Payables00000
Other Working Capital497K(228K)(11K)942K(424K)
Other Non-Cash Items1.39M(7K)718K234K0
Operating Cash Flow(9.35M)(11.55M)(8.53M)(8.83M)(13.05M)
Capital Expenditures(69K)(84K)(33K)(25K)(60K)
Acquisitions (Net)00000
Purchases of Investments0(3.75M)(10.06M)(5.12M)(82.93M)
Sales of Investments3.27M012.06M6.68M10.6M
Other Investing Activities0(3K)3K00
Investing Cash Flow3.2M(3.84M)1.97M1.54M(72.38M)
Debt Repayment00000
Common Stock Issued04.32M6.56M7.94M86.24M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow04.32M6.56M7.94M86.24M
Effect of Forex Changes00000
Net Change in Cash(6.15M)(11.06M)(2K)646K810K
Free Cash Flow(9.42M)(11.63M)(8.57M)(8.85M)(13.11M)

Microbot Medical Inc.

NASDAQ:MBOT

Intrinsic Alpha fair value

Locked

Current Price

$0.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.